Natixis Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.3M | Buy |
+10,109
| New | +$3.3M | 0.01% | 938 |
|
|
2025
Q1 | – | Sell |
-10,453
| Closed | -$2.46M | – | 1603 |
|
|
2024
Q4 | $2.46M | Buy |
10,453
+451
| +5% | +$106K | ﹤0.01% | 1030 |
|
|
2024
Q3 | $2.75M | Buy |
+10,002
| New | +$2.75M | 0.01% | 987 |
|
|
2022
Q2 | – | Sell |
-10,359
| Closed | -$1.69M | – | 1455 |
|
|
2022
Q1 | $1.69M | Sell |
10,359
-2,164
| -17% | -$353K | 0.01% | 1004 |
|
|
2021
Q4 | $2.12M | Sell |
12,523
-7,329
| -37% | -$1.24M | 0.01% | 927 |
|
|
2021
Q3 | $3.75M | Buy |
19,852
+8,461
| +74% | +$1.6M | 0.02% | 735 |
|
|
2021
Q2 | $1.93M | Buy |
+11,391
| New | +$1.93M | 0.01% | 920 |
|